Search

Your search keyword '"Izquierdo Useros, Nuria"' showing total 339 results

Search Constraints

Start Over You searched for: Author "Izquierdo Useros, Nuria" Remove constraint Author: "Izquierdo Useros, Nuria"
339 results on '"Izquierdo Useros, Nuria"'

Search Results

1. Immunization with V987H-stabilized Spike glycoprotein protects K18-hACE2 mice and golden Syrian hamsters upon SARS-CoV-2 infection

2. Immunisation efficacy of a stabilised SARS-CoV-2 spike glycoprotein in two geriatric animal models

3. A monoclonal antibody targeting a large surface of the receptor binding motif shows pan-neutralizing SARS-CoV-2 activity

4. Immune responses associated with mpox viral clearance in men with and without HIV in Spain: a multisite, observational, prospective cohort study

5. Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19

7. Self-sampling monkeypox virus testing in high-risk populations, asymptomatic or with unrecognized Mpox, in Spain

8. Safety and immunogenicity of a recombinant protein RBD fusion heterodimer vaccine against SARS-CoV-2

9. β-Cyclodextrins as affordable antivirals to treat coronavirus infection

10. Tuberculosis-associated IFN-I induces Siglec-1 on tunneling nanotubes and favors HIV-1 spread in macrophages

11. Mycobacterium manresensis induces trained immunity in vitro

12. Kinetics of immune responses elicited after three mRNA COVID-19 vaccine doses in predominantly antibody-deficient individuals

14. Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection

15. Detection of SARS-CoV-2 in a cat owned by a COVID-19–affected patient in Spain

17. Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies

19. Omicron XBB.1.16-Adapted Vaccine for COVID-19: Interim Immunogenicity and Safety Clinical Trial Results.

20. SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cells

21. Plitidepsin as an Immunomodulator against Respiratory Viral Infections

22. Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial

23. Author Correction to: SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cells

25. SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity

26. Pan‐pox‐specific T‐cell responses in HIV‐1‐infected individuals after JYNNEOS vaccination

27. Novel Spike-stabilized trimers with improved production protect K18-hACE2 mice and golden Syrian hamsters from the highly pathogenic SARS-CoV-2 Beta variant

29. Pan‐pox‐specific T‐cell responses in HIV‐1‐infected individuals after JYNNEOS vaccination.

30. Immunization with V987H-stabilized Spike glycoprotein protects K18-hACE2 and golden Syrian hamster upon SARS-CoV-2 infection.

31. Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial

32. Role of Siglecs in viral infections: A double-edged sword interaction

33. Actin- regulated Siglec- 1 nanoclustering influences HIV-1 capture and virus- containing compartment formation in dendritic cells

34. Actin-regulated Siglec-1 nanoclustering influences HIV-1 capture and virus-containing compartment formation in dendritic cells

35. Author response: Actin-regulated Siglec-1 nanoclustering influences HIV-1 capture and virus-containing compartment formation in dendritic cells

36. Cyanovirin-N binds to select SARS-CoV-2 spike oligosaccharides outside of the receptor binding domain and blocks infection by SARS-CoV-2

37. Asymptomatic Monkey Pox Virus Infection: a Self-sampling Screening Intervention Adressed to Gay, Bisexual and Other Men Who Have Sex With Men and Trans Women in Spain

38. Cyanovirin-N binds to select SARS-CoV-2 spike oligosaccharides outside of the receptor binding domain and blocks infection by SARS-CoV-2

39. Randomized clinical trial to assess the impact of oral intervention with cetylpyridinium chloride to reduce salivary SARS‐CoV‐2 viral load

40. β-Cyclodextrins as affordable antivirals to treat coronavirus infection

41. Agreement and differential use of laboratory methods for the detection and quantification of SARS-CoV-2 in experimentally infected animals

43. Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection and humoral responses against different variants of concern in domestic pet animals and stray cats from North‐Eastern Spain

44. Limited Humoral and Specific T-Cell Responses After SARS-CoV-2 Vaccination in PWH With Poor Immune Reconstitution

46. Susceptibility of Domestic Goat (Capra aegagrus hircus) to Experimental Infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) B.1.351/Beta Variant

47. Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial

48. Unraveling the antiviral activity of plitidepsin against SARS-CoV-2 by subcellular and morphological analysis

49. Performance of SARS-CoV-2 Antigen-Detecting Rapid Diagnostic Tests for Omicron and Other Variants of Concern

50. Heterogeneous Infectivity and Pathogenesis of SARS-CoV-2 Variants Beta, Delta and Omicron in Transgenic K18-hACE2 and Wildtype Mice

Catalog

Books, media, physical & digital resources